Tumor Cell Motility

We evaluated the potential therapeutic benefit in a model of chemically induced bladder carcinoma followed by a phase I/II trial applying antimotility drugs in patients which were chemotherapy-resistant and having metastatic bladder cancer

T. Otto; G. L├╝mmen; A. Be; H. Rubben; A. Raz

2011

Scholarcy highlights

  • Chemotherapy and radiotherapy are the current modalities of tumor management
  • Based on previous basic research we have highlighted that the loss of cell-cell adhesion in association with an increased tumor cell motility is an essential feature of the malignant potential of bladder tumors
  • We have attempted therapeutical methods differing from hitherto existing treatments by focusing on a tumor cell function we call cell motility
  • We evaluated the potential therapeutic benefit in a model of chemically induced bladder carcinoma followed by a phase I/II trial applying antimotility drugs in patients which were chemotherapy-resistant and having metastatic bladder cancer
  • Both basic research as well as the results of first translational clinical trials confirmed, that advanced bladder carcinomas can be favorably affected by inhibition of tumor cell motility

Need more features? Save interactive summary cards to your Scholarcy Library.